The IDE allows the Houston, Texas-based company to evaluate its Endoluminal Surgical (ELS) system in colorectal surgery. Its landmark multi-center, open-label study looks at the the ELS system’s safety and performance in robotic endoscopic submucosal dissection (ESD) procedures for the removal of colorectal lesions.

EndoQuest expects 50 subjects to participate in the study. It takes place across five leading U.S. healthcare institutions — Brigham and Women’s Hospital (Boston), Mayo Clinic (Scottsdale), Cleveland Clinic (Cleveland), AdventHealth (Orlando), and HCA Healthcare (Houston).